Skip to Content
Merck
All Photos(7)

Key Documents

G3893

Sigma-Aldrich

Monoclonal Anti-Glial Fibrillary Acidic Protein (GFAP) antibody produced in mouse

clone G-A-5, ascites fluid

Synonym(s):

Anti Gfap, Anti-Gfap, GFAP Antibody - Monoclonal Anti-Glial Fibrillary Acidic Protein (GFAP) antibody produced in mouse, Gfap Antibody, Glial Fibrillary Acidic Protein Antibody, Anti-GFAP

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

conjugate

unconjugated

antibody form

ascites fluid

antibody product type

primary antibodies

clone

G-A-5, monoclonal

species reactivity

rat, human, pig

technique(s)

immunoblotting: suitable
immunocytochemistry: suitable
immunohistochemistry: 1:400 using rat brain sections (alcohol-fixed)
indirect immunofluorescence: suitable
microarray: suitable

isotype

IgG1

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... GFAP(2670)
rat ... Gfap(24387)

General description

Monoclonal anti-glial fibrillary acidic protein (GFAP) (mouse IgG1 isotype) is derived from the hybridoma produced by the fusion of mouse myeloma cells and splenocytes from an immunized mouse. GFAP is the intermediate filament expressed in astrocytes. The gene encoding it is localized on human chromosome 17q21.31.

The isotype is determined using ImmunoTypeTM Kit (Product Code ISO-1) and by a double diffusion immunoassay using Mouse Monoclonal Antibody Isotyping Reagents (Product Code ISO-2).

Intermediate filaments (IFs) with characteristic 10 nm diameter are a distinct class of molecularly heterogenous cytoskeletal filaments defined by ultrastructural, immunological, and biochemical criteria. Intermediate filaments differ significantly from the other cytoskeletal elements of the cell, namely microtubules and microfilaments, and are components of most eukaryotic cells. GFAP (molecular weight of 50 kDa) is the cell specific IF protein in astrocytes.

Specificity

The antibody reacts specifically with GFAP in immunoblotting assays and labels astrocytes, Bergmann glia cells and chondrocytes of elastic cartilage in immunohistochemical staining. The antibody reacts with glial specific antigen in frozen or alcohol-fixed tissue sections.

Immunogen

GFAP from pig spinal cord

Application

Monoclonal Anti-Glial Fibrillary Acidic Protein (GFAP) antibody produced in mouse is suitable for immunohistochemistry at a working dilution of 1:400 using rat brain sections (alcohol-fixed) and microarray analysis. It may be used for immunocytochemical localization of GFAP in human, pig, and rat tissues. It is also suitable for localization of GFAP using immunoblot assays. In indirect immunofluorescent labeling on alcohol-fixed or frozen sections, this antibody stains astrocytes and Bergmann glia cells, gliomas, and other glial cell derived tumors.
The antibody was used as a primary antibody in immunocytochemistry analysis:
  • of primary cerebral microvascular EC cultures to study the effect of microglia on the BBB (blood-brain barrier) and its primary constituents
  • to study the wound healing effects of matrix metalloproteinase-2 that promote recovery after spinal cord injury
  • to study the negative regulation of embryonic neural progenitor cell proliferation by Toll-like receptor 3

Biochem/physiol Actions

The gene GFAP encodes an intermediate filament protein (50kDa) of mature astrocytes, which may be used as a marker for distinguishing astrocytes from other glial cells during development of the central nervous system. Defects in this gene causes Alexander disease. It is a rare disorder of astrocytes in the CNS.

Physical form

Monoclonal Anti-Glial Fibrillary Acidic Protein (GFAP) is provided as ascites fluid containing 15 mM sodium azide as a preservative.

Storage and Stability

For continuous use, store at 2-8 °C for up to one month. For extended storage, the solution may be frozen in working aliquots. Repeated freezing and thawing is not recommended. Storage in "frost-free" freezers is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

GFAP isoforms control intermediate filament network dynamics, cell morphology, and focal adhesions.
Moeton M, et al.
Cellular and Molecular Life Sciences, 73(21) (2016)
TWO CASES WITH DIFFERENT EPILEPSY TYPE AND
DYSMORPHIC FEATURES ASSOCIATED WITH
17q21.31 MICRODELETION SYNDROME
E. UCTEPE, et al.
Genetic Counseling (Geneva, Switzerland), 27(3) (2016)
Midori A Yenari et al.
Stroke, 37(4), 1087-1093 (2006-02-25)
Blood-brain barrier (BBB) disruption after stroke can worsen ischemic injury by increasing edema and causing hemorrhage. We determined the effect of microglia on the BBB and its primary constituents, endothelial cells (ECs) and astrocytes, after ischemia using in vivo and
Characterization of a panel of monoclonal antibodies recognizing specific epitopes on GFAP.
Lin N H, et al.
PLoS ONE, 12(7), e0180694-e0180694 (2017)
Tomokatsu Yoshida et al.
Journal of human genetics, 58(9), 635-638 (2013-08-02)
Alexander disease (AxD) is a rare neurodegenerative disorder. Most patients with AxD have a de novo dominant missense mutation in the glial fibrillary acidic protein (GFAP) gene. Patients with late-onset AxD exhibit a more variable onset and severity than patients

Articles

Frequently asked questions about neural stem cells including NSC derivation, expansion and differentiation.

Frequently asked questions about neural stem cells including NSC derivation, expansion and differentiation.

Frequently asked questions about neural stem cells including NSC derivation, expansion and differentiation.

Frequently asked questions about neural stem cells including NSC derivation, expansion and differentiation.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service